JMP Securities Maintains Market Outperform on Blueprint Medicines, Raises Price Target to $125
Portfolio Pulse from Benzinga Newsdesk
JMP Securities analyst Reni Benjamin maintains a Market Outperform rating on Blueprint Medicines (NASDAQ:BPMC), raising the price target from $114 to $125.
May 03, 2024 | 7:02 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Blueprint Medicines' price target was raised from $114 to $125 by JMP Securities, with a maintained Market Outperform rating.
The increase in price target by JMP Securities reflects a positive outlook on Blueprint Medicines, suggesting confidence in the company's future performance. This analyst endorsement could lead to increased investor confidence and a potential short-term uplift in BPMC's stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100